Skip to main content
SpringerLink
Log in

The Statin Response Gene: KIF6

  • Chapter
  • First Online:
Pharmacogenomic Testing in Current Clinical Practice

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 940 Accesses

Abstract

For over two decades, substantial National efforts have been directed toward ­reducing blood cholesterol levels of the American population with the intent of reducing the burden of cardiovascular events. This initiative was initially prompted by the successful results of the Lipid Research Clinic-Coronary Primary Prevention Trial (LRC-CPPT) that first proved reducing LDL-C resulted in a statistically ­significant reduction in cardiovascular events [2]. Since then an abundance of monotherapy cholesterol-lowering drug trials have consistently reported an approximate 25% relative risk reduction (RRR) for cardiovascular events [3].

It is not good to settle into a set of opinions. At first putting forth great effort to be sure that you have grasped the basics, then practicing so that they may come to fruition is something that will never stop for your whole lifetime. Do not rely on following the degree of understanding that you have discovered, but simply think,

… This is Not Enough

Tsunetomo [1]

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tsunetomo, Y. (1983). Hagakure (1716) (W. S. Wilson, Trans., distributed in the USA by Kodansha America Inc.). Tokyo, Japan: Kodansha America Inc.

    Google Scholar 

  2. Lipid Research Clinics Program. (1984). The lipid research clinics coronary primary prevention trial results: I. Reduction of incidence of coronary heart disease, and II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. The Journal of the American Medical Association, 251, 351–374.

    Article  Google Scholar 

  3. NCEP ATP-III. (2001). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). The Journal of the American Medical Association, 285, 2486–2497.

    Article  Google Scholar 

  4. Superko, H. R., & King, S. III. (2008). Lipid management to reduce cardiovascular risk: A new strategy is required. Circulation, 117, 560–568.

    Article  PubMed  Google Scholar 

  5. Schwartz, R. G., Pearson, T. A., Kalaria, V. G., Mackin, M. L., Williford, D. J., Awasthi, A., et al. (2003). Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: Coronary artery disease regression single photon emission computed tomography monitoring trial. Journal of the American College of Cardiology, 42, 600–610.

    CAS  PubMed  Google Scholar 

  6. AHA Statistical Update. (2006). Heart disease and stroke statistics – 2006 update. Circulation, 113, e85–e151.

    Article  Google Scholar 

  7. Dawber, T. R. (1980). The Framingham study. Cambridge, MA: Harvard University Press.

    Google Scholar 

  8. Brown, S. A., Hutchinson, R., Morrisett, J., Boerwinkle, E., Davis, C. E., Gotto, A. M., et al.; ARIC Study Group. (1993). Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. Arteriosclerosis and Thrombosis, 13, 1139–1158.

    CAS  PubMed  Google Scholar 

  9. Multiple Risk Factor Intervention Trial. (1982). Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. The Journal of the American Medical Association, 248, 1465–1477.

    Article  Google Scholar 

  10. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L. Jr, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206–1252.

    Article  CAS  PubMed  Google Scholar 

  11. Coronary Drug Project Research Group. (1978). Natural history of myocardial infarction in the coronary drug project: Long-term prognostic importance of serum lipid levels. The American Journal of Cardiology, 42, 489–498.

    Article  Google Scholar 

  12. Committee of Principal Investigators. (1980). Report on a WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol. Lancet, ii, 379–384.

    Google Scholar 

  13. Illingworth, D. R., & Bacon, S. (1987). Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. The American Journal of Cardiology, 30, 33G–42G.

    Article  Google Scholar 

  14. NCEP The Expert Panel. (1988). Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (DeWitt S. Goodman – Chairman). Archives of Internal Medicine, 148, 36–69.

    Article  Google Scholar 

  15. Singh, B. K., & Mehta, J. L. (2002). Management of dyslipidemia in the primary prevention of coronary heart disease. Current Opinion in Cardiology, 17, 503–511.

    Article  PubMed  Google Scholar 

  16. O’Keefe, J. H., Cordain, L., Harris, W. H., Moe, R. M., & Vogel, R. (2004). Optimal low-density lipoprotein is 50 to 70 mg/dl. Journal of the American College of Cardiology, 43, 2142–2146.

    PubMed  Google Scholar 

  17. Little, W. C., Constantinescu, M., Applegate, R. J., Kutcher, M. A., Burrows, M. T., Kahl, F. R., et al. (1988). Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation, 78, 1157–1166.

    CAS  PubMed  Google Scholar 

  18. Fuster, V., Badimon, L., Badimon, J., & Chesebro, J. H. (1992). The pathogenesis of coronary artery disease and the acute coronary syndromes. The New England Journal of Medicine, 326, 242–250, 310–318.

    Article  CAS  PubMed  Google Scholar 

  19. Fuster, V., Moreno, P. R., Fayad, Z. A., Corti, R., & Badimon, J. J. (2005). Atherothrombosis and high-risk plaque: Part I: Evolving concepts. Journal of the American College of Cardiology, 46, 937–954.

    Article  PubMed  Google Scholar 

  20. Akosah, K. O., Schaper, A., & Cogbill, C. (2003). Schoenfeld preventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines perform? Journal of the American College of Cardiology, 41, 1475–1479.

    Article  PubMed  Google Scholar 

  21. Shaar, J. A., Muller, J. E., Falk, E., et al. (2004). Terminology for high-risk and vulnerable coronary artery plaques. European Heart Journal, 25, 1077–1082.

    Article  Google Scholar 

  22. Falk, E., Shah, P. K., & Fuster, V. (1995). Coronary plaque disruption. Circulation, 92, 657–671.

    CAS  PubMed  Google Scholar 

  23. Hirokawa, N., & Noda, Y. (2008). Intracellular transport and kinesin superfamily proteins, KIFs: Structure, function, and dynamics. Physiological Reviews, 88, 1089–1118.

    Article  CAS  PubMed  Google Scholar 

  24. Ikegami, K., & Setou, M. (2010). Unique post-translational modifications in specialized microtubule architecture. Cell Structure and Function, 35(1), 15–22.

    Article  PubMed  Google Scholar 

  25. Asbury, C. L. (2005). Kinesin: World’s tiniest biped. Current Opinion in Cell Biology, 17, 89–97.

    Article  CAS  PubMed  Google Scholar 

  26. Gennerich, A., & Vale, R. D. (2009). Walking the walk: How kinesin and dynein coordinate their steps. Current Opinion in Cell Biology, 21, 59–67.

    Article  CAS  PubMed  Google Scholar 

  27. Miki, H., Setou, M., Kaneshiro, K., & Hirokawa, N. (2001). All kinesin superfamily protein, KIF, genes in mouse and human. Proceedings of the National Academy of Sciences of the United States of America, 98, 7004–7011.

    Article  CAS  PubMed  Google Scholar 

  28. Wozniak, M. J., Milner, R., & Allan, V. (2004). N-terminal kinesins: Many and various. Traffic, 5, 400–410.

    Article  CAS  PubMed  Google Scholar 

  29. Hirokawa, N. (1998). Kinesin and dynein superfamily proteins and the mechanism of ­organelle transport. Science, 279, 519–526.

    Article  CAS  PubMed  Google Scholar 

  30. Seiler, S., Kirchner, J., Horn, C., Kallipolitou, A., Woehlke, G., & Schliwa, M. (2000). Cargo binding and regulatory sites in the tail of fungal conventional kinesin. Nature Cell Biology, 2, 333–338.

    Article  CAS  PubMed  Google Scholar 

  31. Barrett, T., Troup, D. B., Wilhite, S. E., et al. (2007). NCBI GEO: Mining tens of millions of expression profiles – database and tools update. Nucleic Acids Research, 35, D760–D765.

    Article  CAS  PubMed  Google Scholar 

  32. King, J. Y., Ferrara, R., Tabibiazar, R., et al. (2005). Pathway analysis of coronary atherosclerosis. Physiological Genomics, 23, 103–118.

    Article  CAS  PubMed  Google Scholar 

  33. Seog, D. H., Lee, D. H., & Lee, S. K. (2004). Molecular motor proteins of the kinesin superfamily proteins (KIFs): Structure, cargo and disease. Journal of Korean Medical Science, 19, 1–7.

    Article  CAS  PubMed  Google Scholar 

  34. Davani, S., Gozalo, C., Gambert, S., Chalmers, D., Gambert, P., Schiele, F., et al. (2010). The polymorphism Trp719Arg in the kinesin-like protein 6 is associated with the presence of late outgrowth endothelial progenitor cells in acute myocardial infarction. Atherosclerosis, 210(1), 48–50.

    Article  CAS  PubMed  Google Scholar 

  35. Schunkert, H., Gotz, A., Braund, P., et al. (2008). Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation, 117, 1675–1684.

    Article  PubMed  Google Scholar 

  36. Shiffman, D., Ellis, S. G., Rowland, C. M., et al. (2005). Identification of four gene variants associated with myocardial infarction. American Journal of Human Genetics, 77(4), 596–605.

    Article  CAS  PubMed  Google Scholar 

  37. The ARIC Investigators. (1989). The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. American Journal of Epidemiology, 129, 687–702.

    Google Scholar 

  38. White, A. D., Folsom, A. R., Chambless, L. E., et al. (1996). Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: Methods and initial two years’ experience. Journal of Clinical Epidemiology, 49, 223–233.

    Article  CAS  PubMed  Google Scholar 

  39. Morrison, A. C., Bare, L. A., Chambless, L. E., et al. (2007). Prediction of coronary heart disease risk using a genetic risk score: The Atherosclerosis Risk in Communities Study. American Journal of Epidemiology, 166, 28–35.

    Article  PubMed  Google Scholar 

  40. Ridker, P. M., Cook, N. R., Lee, I. M., et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. The New England Journal of Medicine, 352, 1293–1304.

    Article  CAS  PubMed  Google Scholar 

  41. Shiffman, D., Chasman, D. I., Zee, R. Y., et al. (2008). A kinesin family member 6 variant is associated with coronary heart disease in the Women’s Health Study. Journal of the American College of Cardiology, 51, 444–448.

    Article  CAS  PubMed  Google Scholar 

  42. Cushman, M., Cornell, E. S., Howard, P. R., Bovill, E. G., & Tracy, R. P. (1995). Laboratory methods and quality assurance in the Cardiovascular Health Study. Clinical Chemistry, 41, 264–270.

    CAS  PubMed  Google Scholar 

  43. Fried, L. P., Borhani, N. O., Enright, P., et al. (1991). The Cardiovascular Health Study: Design and rationale. Annals of Epidemiology, 1, 263–276.

    Article  CAS  PubMed  Google Scholar 

  44. Shiffman, D., O’Meara, E. S., Bare, L. A., et al. (2008). Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 173–179.

    Article  CAS  PubMed  Google Scholar 

  45. Sacks, F. M., Pfeffer, M. A., Moye, L. A., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England Journal of Medicine, 335, 1001–1009.

    Article  CAS  PubMed  Google Scholar 

  46. Shepherd, J., Cobbe, S. M., Ford, I., et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine, 333, 1301–1307.

    Article  CAS  PubMed  Google Scholar 

  47. Iakoubova, O. A., Tong, C. H., Rowland, C. M., et al. (2008). Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: The CARE and WOSCOPS trials. Journal of the American College of Cardiology, 51, 435–443.

    Article  CAS  PubMed  Google Scholar 

  48. Packard, C. J., O’Reilly, D. S., Caslake, M. J., et al. (2000). Lipoprotein-associated ­phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine, 343, 1148–1155.

    Article  CAS  PubMed  Google Scholar 

  49. Iakoubova, O., Robertson, M., & Tong, C. H. (2009). KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: Results from the PROSPER study. (Manuscript under review).

    Google Scholar 

  50. The Wellcome Trust Control Consortium. (2007). Genome wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447, 661–677.

    Article  Google Scholar 

  51. Stewart, A. F., Dandona, S., Chen, L., et al. (2009). Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. Journal of the American College of Cardiology, 53, 1471–1472.

    Article  CAS  PubMed  Google Scholar 

  52. Williams, P. D. (2010). Survival and other biases affecting case-control genetic studies of coronary heart disease. Current Molecular Pharmacology (in submission).

    Google Scholar 

  53. Shiffman, D., Rowland, C. M., Thompson, J., Hall, A. S., Devlin, J. J., & Saman, N. J. (2009). The KIF6719ARG allele is associated with increased risk of coronary heart disease among males in the Wellcome Trust Case Control Consortium Study of Coronary Heart Disease. Poster presentation at the British Atheroslcerosis Society Autumn Meeting: Genetics of Complex Diseases, Queens’ College, Cambridge, UK.

    Google Scholar 

  54. Tham, L. S., Goh, B. C., Nafziger, A., Guo, J. Y., Wang, L. Z., Soong, R., et al. (2006). A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clinical Pharmacology and Therapeutics, 80, 346–355

    Article  CAS  PubMed  Google Scholar 

  55. Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., et al. (2005). The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood, 106(7), 2329–2333. Epub 2005 Jun 9.

    Article  CAS  PubMed  Google Scholar 

  56. Voora, D., Eby, C., Linder, M. W., Milligan, P. E., Bukaveckas, B. L., McLeod, H. L., et al. (2005). Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and Haemostasis, 93, 700–705.

    CAS  PubMed  Google Scholar 

  57. Antman, E. M., Wiviott, S. D., Murphy, S. A., Voitk, J., Hasin, Y., Widimsky, P., et al. (2008). Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis in Myocardial Infarction) analysis. Journal of the American College of Cardiology, 51, 2028–2033.

    Article  CAS  PubMed  Google Scholar 

  58. Schatz, I. J., Masaki, K., Yano, K., Chen, R., Rodriguez, B. L., & Curb, J. D. (2001). Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet, 358, 351–355.

    Article  CAS  PubMed  Google Scholar 

  59. Shipley, M. J., Pocock, S. J., & Marmot, M. G. (1991). Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. British Medical Journal (Clinical Research Ed.), 303, 89–92.

    Article  CAS  PubMed  Google Scholar 

  60. Weverling-Rijnsburger, A. W., Blauw, G. J., Lagaay, A. M., Knook, D. L., Meinders, A. E., & Westendorp, R. G. (1997). Total cholesterol and risk of mortality in the oldest old. Lancet, 350, 1119–1123.

    Article  CAS  PubMed  Google Scholar 

  61. Ray, K. K., Bach, R. G., Cannon, C. P., et al. (2006). Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. European Heart Journal, 27(19), 2310–2316.

    Article  CAS  PubMed  Google Scholar 

  62. Shepherd, J., Blauw, G. J., Murphy, M. B., et al. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet, 360(9346), 1623–1630.

    Article  CAS  PubMed  Google Scholar 

  63. Iakoubova, O. A., Robertson, M., Tong, C. H., Roswland, C. M., Catanese, J. J., Blauw, G. J., et al. (2010). KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: Results from the PROSPER study. European Journal of Cardiovascular Prevention and Rehabilitation, 17(4), 455–461.

    Article  PubMed  Google Scholar 

  64. Cannon, C. P., Braunwald, E., McCabe, C. H., et al. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine, 350, 1495–1504.

    Article  CAS  PubMed  Google Scholar 

  65. Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., et al. (2008). Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: Results from the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology, 51, 449–455.

    Article  CAS  PubMed  Google Scholar 

  66. Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J. T., Kaplan, C., et al. (1990). Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England Journal of Medicine, 323, 1289–1298.

    Article  CAS  PubMed  Google Scholar 

  67. Brown, G. B., Zhao, X. Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., et al. (2001). Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England Journal of Medicine, 345, 1583–1592.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Celera Corp., 1401 Harbor Bay Parkway, Alameda, CA, 94502, USA

    H. Robert Superko

Authors
  1. H. Robert Superko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tom White
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Forrester
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Spencer King III
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Robert Superko .

Editor information

Editors and Affiliations

  1. San Francisco General Hospital, Clinical Chemistry Lab., University of California, San Francisco, 1001 Potrero Ave., San Francisco, 94110, California, USA

    Alan H. B. Wu

  2. Department of Pathology, Clinical Pharmacogenomics Program, University of Chicago, S. Maryland Ave. 5841, Chicago, 60637, Illinois, USA

    Kiang-Teck J. Yeo

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Superko, H.R., White, T., Forrester, J., King, S. (2011). The Statin Response Gene: KIF6. In: Wu, A., Yeo, KT. (eds) Pharmacogenomic Testing in Current Clinical Practice. Molecular and Translational Medicine. Humana Press. https://doi.org/10.1007/978-1-60761-283-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-283-4_11

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-282-7

  • Online ISBN: 978-1-60761-283-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation